New drug tested for Tough-to-Treat blood cancer
NCT ID NCT07245251
Summary
This early-phase study aims to test the safety and initial effectiveness of an investigational drug called STR-P004 in adults with a specific type of acute lymphoblastic leukemia (ALL) that has returned or not responded to other treatments. The study will enroll a small group of participants to receive the drug at different dose levels to find a safe and potentially effective amount. The main goal is to understand the side effects and see if the drug shows any early signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.